Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data
Source: SeekingAlpha
2026-01-08 17:45:37 ET
The last time I spoke about Immuneering Corporation ( IMRX ) it was in a Seeking Alpha article entitled "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst." With respect to this article, I mentioned that this company was able to release positive data from its phase 2a study using its drug atebimetinib + modified gemcitabine/nab-paclitaxel [mGnP] to treat patients with 1st-line pancreatic cancer. There was a landmark 83% overall-survival [OS] observed at 9 months....
Read the full article on Seeking Alpha
For further details see:
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data
Immuneering Corporation
NASDAQ: IMRX
IMRX Trading
0.2% G/L:
$5.065 Last:
336,290 Volume:
$4.95 Open:
IMRX Latest News
February 18, 2026 04:05:00 pm
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
January 07, 2026 04:00:00 pm
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
IMRX Stock Data
$324,141,234
49,783,445
3.08%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
